Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OSE Immunotherapeutics logo — Immuno-Oncology and Immuno-Inflammation - Breakthrough Immu...

OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Founded 2012 France France 76 employees Grant Total: $53.95M Biotechnology, Medical Devices +1

General Information

Company Name OSE Immunotherapeutics
Founded Year 2012
Location France France
Employees 76
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with OSE Immunotherapeutics. To contact OSE Immunotherapeutics, visit ose-immuno.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OSE Immunotherapeutics compare?

A PDF of OSE Immunotherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OSE Immunotherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated biotech company founded in 2012, headquartered in France. The company focuses on developing first-in-class assets targeting cancer and inflammatory diseases. Its well-balanced first-in-class clinical pipeline includes promising products such as Tedopi® for non-small cell lung cancer (NSCLC) and OSE-279 in the advanced preclinical stage. OSE Immunotherapeutics has also formed partnerships with companies like Veloxis and Boehringer Ingelheim for the development of drugs in areas such as transplantation and advanced solid tumors. Moreover, the company aims to generate substantial value from its proprietary drug discovery platforms, namely BiCKI® focused on immuno-oncology and Myeloid platform targeting immuno-inflammation. Its most advanced BiCKI® candidate is targeting anti-PD1xIL-7, demonstrating its commitment to deliver next-generation first-in-class immunotherapeutics. OSE Immunotherapeutics recently received a €8.40M grant investment on April 10, 2024, with the backing of France 2030. With a strong focus on immuno-oncology and immuno-inflammation, the company shows great potential in addressing unmet medical needs in these critical therapeutic areas.

Business keywords: biotech company, immunotherapy, cancer, inflammatory diseases, drug discovery, BiCKI platform, Myeloid platform, clinical pipeline, T-cell specific immunotherapy, CD47/SIRPα pathway, oncology research, immune system modulation, transplantation, clinical trials, cancer treatment

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €8.40M 1
France 2030
10 Apr 2024
Grant €200.00K 2
Pays de la Loire region, Government of France
01 Aug 2023
Debt Financing €10.00M 1
European Investment Bank
09 Jul 2021
Funding Round €10.70M -
23 May 2021
Grant €5.20M 1
Bpifrance
Bpifrance
01 Dec 2020
Grant €9.20M 1
Bpifrance
Bpifrance
19 Jul 2017
Post IPO Equity €10.25M -
28 Dec 2016

OSE Immunotherapeutics Alternatives & Competitors

View All Alternatives
OSE Immunotherapeutics vs
Kanaph Therapeutics
Kanaph Therapeutics Korea South

We are the leader of next generation immuno-oncology and autoimmune diseases.

Series B
16 employees
Biotechnology, Pharmaceutical
Compare OSE Immunotherapeutics vs Kanaph Therapeutics
OSE Immunotherapeutics vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
Compare OSE Immunotherapeutics vs Apollomics
OSE Immunotherapeutics vs
Tetralogic Pharmaceuticals
Tetralogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
Also compare with: OSE Immunotherapeutics vs Jounce Therapeutics, Inc. Jounce Therapeutics, Inc. View all alternatives

FAQ About OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients
OSE Immunotherapeutics was founded in 2012.
OSE Immunotherapeutics is headquartered in France.
OSE Immunotherapeutics operates in Biotechnology, Medical Devices and Pharmaceutical. Its work centres on biotech company, immunotherapy, cancer and inflammatory diseases.
OSE Immunotherapeutics has approximately 76 employees.
OSE Immunotherapeutics has completed 7 funding rounds, raising a total of $53.95M. The latest funding stage is Grant.
Top alternatives and competitors to OSE Immunotherapeutics include Kanaph Therapeutics, Apollomics, Tetralogic Pharmaceuticals, Jounce Therapeutics, Inc., Alpha Cancer Technologies Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OSE Immunotherapeutics and Kanaph Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OSE Immunotherapeutics, https://bouncewatch.com/company/ose-immunotherapeutics, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout